ta-cin/gpi-0100
Vaccineexperimental
Clinical trial activity
3 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started May 1, 2016 (NCT02405221)
Timeline
2010s
- Jan 1, 2016
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Tumor antigensImmunity, active
immunity, active - tumor antigens
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- ta-cin/gpi-0100
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05132803 | Phase 1 | Feb 28, 2022 | Johns Hopkins University |
| NCT03913117 | Phase 1 | Jun 30, 2019 | Johns Hopkins University, University of Alabama, Birmingham |
| NCT02405221 | Phase 1 | May 1, 2016 | Johns Hopkins University |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Johns Hopkins University | Academic/Hospital | 3 | 2 | 1 | 2016 |
| University of Alabama, Birmingham | Academic/Hospital | 1 | 1 | 1 | 2019 |
2 organizations
Page 1 / 1